Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (162)	4/9/2002 5:12:08 PM
From: Al Collard	Respond to of 164

SYNSORB Biotech Inc. Provides Corporate Update and Reports Year-End 2001 Results newswire.ca

To: Jim Oravetz who wrote (162)	5/10/2002 12:20:53 PM
From: Jim Oravetz	Respond to of 164

Oncolytics Biotech Gets 14.6% BCY Stake DOW JONES NEWSWIRES TORONTO -- Pursuant to an agreement between Oncolytics Biotech Inc. (ONCY) and Synsorb Biotech Inc. (T.SYB), Oncolytics will receive all of the BCY LifeSciences Inc. (V.BCY) common shares and future rights to BCY shares held by Synsorb, giving it a 14.6% stake in BCY. In a news release, BCY said Oncolytics is also eligible for an additional 400,000 shares as milestones are achieved. The deal has been approved by shareholders of both Oncolytics and Synsorb. In a related development, BCY LifeSciences said it is close to finalizing the protocol for its Phase II clinical trial for cystic fibrosis, putting it on track to initiate the trial later this year. BCY LifeSciences is a development-stage biopharmaceutical company. Company Web Sites: bcylifesciences.com, synsorb.com and oncolyticsbiotech.com